Filing Flows › CervoMed (CRVO) › Q3 2025
CervoMed (CRVO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
CervoMed (CRVO) reported revenue of $323K for the third quarter 2025 (Q3 2025), -83% from a year earlier and -82% from the quarter before.
CervoMed, Q3 2025: revenue $323K (-83% year over year), net loss $7.7M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $323K | -82% | -83% |
| Operating profit | −$8.0M | — | — |
| Net earnings | −$7.7M | — | — |
| Operating cash flow | −$6.5M | — | — |
What changed
Revenue was $323K in Q3 2025, down 83% year over year and down 82% from the previous quarter.
Operating costs exceeded revenue by $8.0M, an operating margin of -2493.8%. Total costs grew 14% against a revenue fall of 83%. The fastest-growing cost line was Research & development (+18%). The quarter ended with a net loss of $7.7M, wider than the previous quarter's $6.3M loss.
Operating cash flow was −$6.5M. Non-cash charges added back $292K of share-based compensation. Working capital and other items added $1.0M.
Questions
What was CervoMed's revenue in the third quarter 2025?
CervoMed (CRVO) reported revenue of $323K for the third quarter 2025 (Q3 2025), -83% from a year earlier and -82% from the quarter before.
Source: CervoMed 10-Q on SEC EDGAR.